San Diego, United States
AVIVA Biosciences is a biotechnology startup founded in 1997. The company specializes in inventing devices and assays to advance the study of eukaryotic cells, focusing on safety screening with emphasis on ion channels. AVIVA serves as a contract research organization providing safety screening specializing in cardiovascular mechanics, electrophysiology, and safety. The company offers customizable assays, including Langendorff, Purkinje, Trabeculae, myocytes, and clonal lines from various species, with a range of applications such as action potential prolongation, ion channel effect profiling, and contraction.
One of AVIVA's significant innovations is the RedSift Filter System, a proprietary instrument and filter array system engineered to separate mixed cell populations based on cell size, shape and conformity. This technology is designed to filter whole blood, bone marrow, or other biological fluids, allowing specific cell types to pass through while retaining all leukocytes, including lymphocytes, and any rare cells in the circulation. The gentle process of cell recovery avoids harsh chemicals and gradient centrifugation, consistently recovering more than 90% of total nucleated cells in a sample, making it valuable for various cytometry applications and the analysis of rare cell populations.
Additionally, AVIVA is known for its Sealchip16, the first commercialized voltage clamp biochip capable of performing gigaohm seals, which has become the gold standard for automated voltage clamp. In 2010, an upgraded version of Sealchip16 was released to provide better success rates with certain cell types. The company's commitment to innovation and advancing cell study is further emphasized by its offerings of tutorials on PatchXpress, Cell Isolation, and Voltage Clamp through its website.
AVIVA Biosciences is positioned at the intersection of biotechnology and research, offering a promising opportunity for investment in a company dedicated to advancing the understanding of eukaryotic cells and safety screening through innovative technologies and assays.